Prelude Capital Management, LLC Clovis Oncology, Inc. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $228 - $1,248	-76 Reduced 10.83%	626 $7,000
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $23 - $92	-6 Reduced 0.85%	702 $3,000
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $25 - $51	-2 Reduced 0.28%	708 $11,000
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $12,273 - $21,044	695 Added 4633.33%	710 $18,000
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $225,075 - $632,262	-19,353 Reduced 99.92%	15 $0
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $342,689 - $577,332	11,668 Added 151.53%	19,368 $569,000
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $107,168 - $158,995	2,548 Added 49.46%	7,700 $350,000
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $234,411 - $316,726	4,677 Added 984.63%	5,152 $272,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $432,213 - $633,673	-7,492 Reduced 94.04%	475 $32,000
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $535,143 - $675,681	7,967	7,967 $656,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.